May 17th 2024
The researchers identified age, tumor metastasis, and surgical treatment as key independent prognostic factors for cardiovascular mortality in patients with ovarian cancer, highlighting the need for individualized treatment and surveillance strategies.
FDA Grants Fast Track Designation to IDE161 for BRCA+, Platinum-Resistant Advanced Ovarian Cancer
September 30th 2023The FDA has granted fast track designation to IDE161 for the treatment of adult patients with advanced or metastatic ovarian cancer harboring germline or somatic BRCA1/2 mutations who are platinum resistant and have received prior treatment with antiangiogenic and poly-ADP ribose polymerase, or PARP, inhibitor therapies.
Read More
Atezolizumab Misses PFS End Point in Recurrent Epithelial Ovarian Cancer
September 12th 2023Results from ATLANTE/ENGOT-ov29 show that atezolizumab did not significantly improve progression-free survival (PFS) compared with placebo plus bevacizumab for patients with platinum-sensitive ovarian cancer.
Read More
TTFields Plus Paclitaxel Misses OS End Point in Platinum-Resistant Ovarian Cancer
September 9th 2023The phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 trial found the addition of tumor treating fields (TTFields) to paclitaxel did not provide a statistically significant improvement in overall survival (OS) vs paclitaxel alone for patients with platinum-resistant ovarian cancer, failing to meet its primary end point.
Read More
Study Highlights Factors Linked to ED Readmission Following Ovarian Carcinoma Surgery
September 6th 2023Out of several factors, surgical complications were the only factor independently associated with emergency department (ED) readmission among patients who underwent surgery for ovarian carcinoma.
Read More
The platinum drugs most effective in treating ovarian cancer are in limited supply due to the drug shortage; the government proposes a plan to prevent hospitals from redistributing Medicaid money; physicians ask for help in treating the high number of children with mental illness coming to the emergency department.
Read More
Exercise May Reduce Chemotherapy-Induced Peripheral Neuropathy Symptoms in Women With Ovarian Cancer
August 9th 2023While there is currently no effective treatment for chemotherapy-induced peripheral neuropathy, one of the most common and severe adverse effects for patients who have undergone chemotherapy for ovarian cancer, a 6-month aerobic exercise intervention significantly improved symptoms.
Read More
Niraparib Maintenance Therapy Improves PFS by 55% in Advanced Ovarian Cancer
August 2nd 2023Results of the phase 3 PRIME study showed that treatment with niraparib with an individualized starting dose significantly extended progression-free survival (PFS) and reduced the risk of disease progression or death by 55% compared with placebo.
Read More
Kathleen N. Moore, MD, MS, on Groundbreaking Result in MIRASOL: “This Is What Patients Want”
June 30th 2023This interview with the lead investigator of the MIRASOL trial, which was presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, will appear with coverage of ASCO in the upcoming issue of Evidence-Based Oncology.
Read More
FDA Pauses Upifitamab Rilsodotin Trials in Platinum-Sensitive Ovarian Cancer
June 23rd 2023Following safety reports of bleeding events after treatment with upifitamab rilsodotin among patients with platinum-sensitive ovarian cancer, the FDA places a partial clinical hold on enrollment for the UP-NEXT and UPGRADE-A trials.
Read More